Instead of focusing only on removing harmful protein buildup in the brain, the experimental drug targets several changes linked to Alzheimer’s disease at the same time, raising hopes for a more effective treatment.
The drug, known as KCL-286, was originally developed to treat spinal cord injuries. In a recent study using mice, researchers found that it repaired harmful DNA damage in brain cells, reduced inflammation in the brain, and improved several biological changes associated with Alzheimer’s disease.
Alzheimer’s is the most common form of dementia and is marked by memory loss, confusion, and a gradual decline in thinking and reasoning abilities.
Current treatments mainly help manage symptoms and often focus on reducing amyloid or tau proteins naturally found in the brain.
However, scientists believe that Alzheimer’s develops through several interconnected biological processes, making it important to target more than one pathway.
The findings suggest that KCL-286 may offer a broader approach by tackling multiple causes of the disease at once.
According to the researchers, the drug repaired DNA damage that can contribute to the death of brain cells while also reducing inflammation, another major factor believed to speed up the progression of Alzheimer’s.
One of the biggest advantages of KCL-286 is that it has already completed Phase 1 clinical trials, where it was found to be safe and well tolerated in humans.
Because this early safety testing has already been completed, researchers believe the drug could move into Alzheimer’s clinical trials much faster than a newly developed medicine.
Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London, said KCL-286 is a first-in-class, orally available small molecule that has successfully passed Phase 1 human safety and tolerability trials.
“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,” Corcoran said.
Although the results are encouraging, the researchers caution that the findings are based on animal studies. Further clinical trials involving people with Alzheimer’s disease will be needed to determine whether the drug is safe and effective for treating the condition.
If future studies confirm these early findings, KCL-286 could represent an important step toward developing treatments that address the complex biology of Alzheimer’s rather than focusing on a single target.
Leave a Reply